141 related articles for article (PubMed ID: 1282015)
1. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
[TBL] [Abstract][Full Text] [Related]
3. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
[TBL] [Abstract][Full Text] [Related]
4. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
[TBL] [Abstract][Full Text] [Related]
5. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
6. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
Boucher CA; O'Sullivan E; Mulder JW; Ramautarsing C; Kellam P; Darby G; Lange JM; Goudsmit J; Larder BA
J Infect Dis; 1992 Jan; 165(1):105-10. PubMed ID: 1370174
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
[TBL] [Abstract][Full Text] [Related]
8. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
Sheehy N; Desselberger U
J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
St Clair MH; Hartigan PM; Andrews JC; Vavro CL; Simberkoff MS; Hamilton JD
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):891-7. PubMed ID: 8315574
[TBL] [Abstract][Full Text] [Related]
10. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
[TBL] [Abstract][Full Text] [Related]
11. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
[TBL] [Abstract][Full Text] [Related]
12. Characterization of HIV isolates arising after prolonged zidovudine therapy.
Mayers DL; McCutchan FE; Sanders-Buell EE; Merritt LI; Dilworth S; Fowler AK; Marks CA; Ruiz NM; Richman DD; Roberts CR
J Acquir Immune Defic Syndr (1988); 1992; 5(8):749-59. PubMed ID: 1381438
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.
Spencer LT; Ogino MT; Dankner WM; Spector SA
J Infect Dis; 1994 Mar; 169(3):491-5. PubMed ID: 7908924
[TBL] [Abstract][Full Text] [Related]
14. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
Calderón EJ; Torres Y; Medrano FJ; Luque F; Larder B; Rey C; Sánchez-Quijano A; Lissen E; Leal M
Eur J Clin Microbiol Infect Dis; 1995 Jun; 14(6):512-9. PubMed ID: 7588824
[TBL] [Abstract][Full Text] [Related]
15. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.
Angarano G; Monno L; Vivirito MC; Appice A; Romanelli C; Giannelli A; La Grasta L; Fracasso C; Fiore JR; Milazzo F
AIDS Res Hum Retroviruses; 1996 Jul; 12(11):969-75. PubMed ID: 8827212
[TBL] [Abstract][Full Text] [Related]
16. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
[TBL] [Abstract][Full Text] [Related]
17. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
[TBL] [Abstract][Full Text] [Related]
18. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.
Katzenstein TL; Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
Antivir Ther; 1996 Dec; 1(4):246-54. PubMed ID: 11324827
[TBL] [Abstract][Full Text] [Related]
19. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
Kuritzkes DR; Bell S; Bakhtiari M
AIDS; 1994 Jul; 8(7):1017-9. PubMed ID: 7524542
[No Abstract] [Full Text] [Related]
20. Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children.
Mellado MJ; Cilleruelo MJ; Ortiz M; Villota J; García M; Perez-Jurado ML; Barreiro G; Martín-Fontelos P; Bernal A
Pediatr Infect Dis J; 1997 Nov; 16(11):1032-7. PubMed ID: 9384335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
